Spero Therapeutics Analyst Ratings
H.C. Wainwright Maintains Spero Therapeutics(SPRO.US) With Buy Rating, Maintains Target Price $7
Promising Clinical Developments Underpin Buy Rating for Spero Therapeutics
TD Cowen Upgrades Spero Therapeutics(SPRO.US) to Buy Rating
Spero Therapeutics Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Spero Therapeutics, Maintains $7 Price Target
H.C. Wainwright Maintains Spero Therapeutics(SPRO.US) With Buy Rating, Maintains Target Price $7
Buy Rating Affirmed on Spero Therapeutics as Drug Pipeline Progresses
Spero Therapeutics Analyst Ratings
Buy Rating Affirmed for Spero Therapeutics Amidst Drug Pipeline Progress and Strategic Partnerships
Analysts Conflicted on These Healthcare Names: Spero Therapeutics (SPRO) and Coherus Biosciences (CHRS)
Spero Therapeutics Analyst Ratings
Spero Therapeutics Analyst Ratings
Spero Therapeutics' Robust Drug Pipeline and Positive Trial Advancements Prompt Buy Rating
TD Cowen Sticks to Its Hold Rating for Spero Therapeutics (SPRO)
TD Cowen Keeps Their Hold Rating on Spero Therapeutics (SPRO)
Analysts Offer Insights on Healthcare Companies: Durect (DRRX), Spero Therapeutics (SPRO) and EFFECTOR Therapeutics (EFTR)
Spero Therapeutics Analyst Ratings
Buy Rating for Spero Therapeutics: Impact of New CFO and Imminent Phase 3 Trial Program
Spero Therapeutics (SPRO) Receives a Buy From H.C. Wainwright